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STUDY PROTOCOL

Developing shelf‑stable Microbiota Directed
Complementary Food (MDCF) prototypes
for malnourished children: study protocol
for a randomized, single‑blinded, clinical study
Ishita Mostafa1,2, Shah Mohammad Fahim1* , Subhasish Das1,3, Md Amran Gazi1, Md. Mehedi Hasan1,
Kazi Nazmus Saqeeb1, Mustafa Mahfuz1,2, Hannah B. Lynn4,5, Michael J. Barratt4,5,6, Jeffrey I. Gordon4,5,6 and
Tahmeed Ahmed1,7,8,9

Abstract
Background: Childhood undernutrition is a major public health concern that needs special attention to achieve
2025 global nutrition targets. Moderate acute malnutrition (MAM), manifest as wasting (low weight-for-height),
affects 33 million children under 5, yet there are currently no global guidelines for its treatment. We recently performed a randomized-controlled clinical study of a microbiota-directed complementary food formulation (MDCF-2)
in 12-18-month-old Bangladeshi children with MAM. The results revealed that MDCF-2, freshly prepared each day,
produced a significantly greater improvement in ponderal growth than a standard ready-to-use supplementary food
(RUSF), an effect that is associated with repair of the disrupted gut microbial community development that occurs in
children with MAM. To test the generalizability of these results in acutely malnourished children at other sites, there is
a pressing need for a packaged, shelf-stable, organoleptically-acceptable formulation that is bioequivalent to MDCF2. This report describes the protocol for a clinical study to evaluate candidate formulations designed to meet these
criteria.
Methods: A randomized single-blind study will be conducted in 8-12-month-old Bangladeshi children with MAM
to compare the efficacy of alternative shelf-stable MDCF prototypes versus the current MDCF-2 formulation that is
produced fresh each day. V4-16S rDNA amplicon and shotgun sequencing datasets will be generated from faecal
DNA samples collected from each child enrolled in each group prior to, during, and after treatment to determine the
abundances of MDCF-2-responsive bacterial taxa. Efficacy will be assessed by quantifying the change in representation of MDCF-2-responsive gut bacterial taxa after 4-weeks of treatment with freshly prepared MDCF-2 compared to
their changes in abundance after treatment with the prototype MDCFs. Equivalence will be defined as the absence of
a statistically significant difference, after 4-weeks of treatment, in the representation of faecal bacterial taxa associated
with the response to MDCF-2 in participants receiving a test MDCF.
Discussion: This trial aims to establish acceptability and equivalence with respect to microbiota repair, of scalable,
shelf-stable formulations of MDCF-2 in 8-12-month-old Bangladeshi children with moderate acute malnutrition.
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Trial registration: ClinicalTrials.gov (NCT05094024). The trial has been registered before starting enrolment on 23
October 2021.
Keywords: Moderate Acute Malnutrition, Microbiota Directed Complementary Food, Gut Microbiota

Background
Worldwide, 47 million children under 5-years-of-age
are acutely malnourished (wasted), while 149 million
are short for their age (stunted) [1, 2]. In Bangladesh,
the prevalence of stunting, underweight and wasting
among children under 5 were 31%, 22% and 8%, respectively [3]. However, the prevalence of different forms of
childhood malnutrition, especially acute malnutrition, is
likely to increase as millions of children in low- and middle-income countries around the world are experiencing
acute hunger and food insecurity as a result of the ongoing Covid-19 pandemic and related economic turbulence
[4]. Moderate acute malnutrition (MAM) in children is
defined by anthropometry based on the WHO criteria
[(i.e., weight-for-height (WHZ) between 2 and 3 standard
deviations below the median of the WHO Child Growth
Standards) and/or upper mid-upper-arm- circumference (MUAC) between 115mm and 125mm] [5]. There
are currently no global guidelines for the treatment for
MAM. Therefore, there is a great need for effective nutritional interventions that could be used to treat undernutrition in infants/children and simultaneously facilitate
progress towards achieving the WHO global nutrition
targets set for 2025 [6].
Our recent work in undernourished Bangladeshi children has focused on the contribution of the gut microbiota to their nutritional status. Using culture-independent
methods to analyze serially collected faecal samples collected from healthy children and from those with MAM,
we found that MAM is associated with impaired microbiota development (microbiota ‘immaturity’) [7, 8]. We
showed that this immaturity is not repaired by standard
nutritional interventions [7, 8]. Furthermore, preclinical
studies using gnotobiotic animal models disclosed that
colonization with gut communities from undernourished children transmitted impaired weight gain and
bone growth phenotypes, plus immune and metabolic
abnormalities [9]. Based on these observations, gnotobiotic mice and gnotobiotic piglets were used to screen
combinations of culturally acceptable food staples that
are commonly consumed as complementary foods in
Bangladesh for their ability to increase the fitness of bacterial taxa underrepresented in the immature microbiota
of acutely malnourished children. This effort led to the
development of several microbiota-directed complementary food (MDCF) prototypes [8, 10]. Three of these
formulations were compared to an existing ready-to-use

supplementary food (RUSF) in a 1-month randomized
controlled ‘pre-POC’ study in 12-18-month-old children with MAM living in an urban slum in the Mirpur
area of Dhaka, Bangladesh [8, 10]. One of these formulations (MDCF-2) ‘repaired’ the gut microbial community
to state similar to that found in aged-matched healthy
Mirpur children, and altered the abundances of plasma
proteins in directions that were indicative of improved
growth/health status.
We subsequently performed a larger, longer proof-ofconcept (POC) study to compare the effects of MDCF-2
and RUSF on the growth of 12-18-month old children
with MAM. Despite its lower caloric density (4.30 versus 4.96 kcal/g), children who received MDCF-2 exhibited a significantly faster rate of weight gain during the
3-month period of intervention compared to those consuming RUSF. This improvement was associated with an
increase in the abundance of the underrepresented bacterial taxa that MDCF-2 was designed to promote [11].
Both the pre-POC and POC studies described above
used a formulation of MDCF-2 that was prepared fresh
each day at icddr,b facilities. The objective of the current study is to test industrially manufactured, packaged,
shelf-stable formulations of MDCF that would greatly
facilitate the expansion of tests of its efficacy to other
sites/populations. These studies require development of
a uniform formulation that satisfies the following criteria: (i) biological activity equivalent to the current freshly
prepared formulation of MDCF-2; (ii) shelf-stable, free
of microbial contamination, with satisfactory organoleptic properties; (iii) conforms to existing WHO/UNICEF
specifications for a nutritional intervention for treating
MAM; (iv) can be produced at scale using ingredients
from sustainable sources at an affordable price with the
potential for distribution across national boundaries.
Here, we present the research protocol for a pre-POC
study of candidate shelf-stable MDCF prototypes in Mirpur area of Dhaka city, Bangladesh.

Methods
Goal and objectives

The primary goal of the trial is to compare the efficacy of
a shelf-stable formulation of MDCF-2 with that of freshly
prepared MDCF-2 and assess its organoleptic acceptability. We will also test the extent to which alternative
MDCF formulations are able to repair the gut microbiota
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of children with MAM compared to the repair produced
by the current MDCF-2 formulation.
Study design

Figure 1 describes the design of this randomized single-blind pre-POC trial that was approved by the Ethical Research Committee at the icddr,b on 28 June 2021
(PR- 21019).
It will be conducted in three phases. The first 2 weeks
after enrolment are a ‘run-in’ phase where children are
followed on their normal diets, without nutritional intervention. During this phase, collection of fecal samples
will allow the baseline configuration of their microbiota
to be characterized prior to treatment. Subsequently,
participants will be randomized to receive one of the
food prototypes, administered under supervision, twice
daily for 4 weeks. Fecal samples collected at the end of
the intervention phase will be used to assess the extent
of microbiota repair produced by each treatment. After
completion of the intervention, each child will be followed for another 2 weeks. Fecal samples collected during this phase will be used to assess the durability of the
microbiota repair. Blood samples will be collected at
baseline and at the end of the treatment phase to quantify
levels of plasma protein biomarkers/effectors of healthy
growth [11].
Eligible participants are 8-12-month-old Bangladeshi
children with MAM. The study will be conducted among
members of the slum population in Baoniabad of Mirpur,
one of the 21 administrative units of the nation’s capital,
Dhaka. Mirpur was selected because it is inhabited by

Fig. 1 Study design
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poor and lower middle-class families, and because residential and sanitary conditions are typical of congested
urban settlements. Additionally, the investigators have
established several field sites in this area and have ongoing research activities in the community.
Screening, consent & enrolment of study participants

A trained Field Research Assistant (FRA) will explain the
study design and methodology in detail, describe potential risks and benefits, answer any questions from the
parent(s), and invite the parent(s) to enroll their child in
the study. If the parent(s) are interested, they will proceed
to screening and consenting. Eligibility will be determined based on the inclusion and exclusion criteria listed
in Table 1.
If a subject is eligible to participate, the consent process
will consist of a thorough review of the written consent
form in a manner appropriate for the parents’ literacy
level. Prior to parental signing of the consent form, the
child will undergo thorough clinical examination by
study physician. In addition, there may be a recommendation that a child undergo laboratory tests to exclude
any organic diseases or any other causes of secondary
malnutrition. During this period, parents of the participants will have an opportunity to ask any questions about
the study. If the FRA determines that participants have
demonstrated adequate comprehension of the study, the
consent form will be signed by the FRA and the child’s
parent(s). If the parent(s) are not sufficiently literate
to read and/or sign the consent form, consenting and a
thumbprint signature will be obtained in the presence of
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Table 1 Inclusion/exclusion criteria of the study participants
Inclusion
Parent(s) willing to sign consent form
Child aged 8–12 months
WLZ score < -2 to -3 without bilateral pedal edema at the time of randomization
Parent(s) willing to bring the child to the feeding centre according to the pre-defined schedule
Exclusion
Meeting any of the following criteria will exclude a subject from study participation –
Medical conditions: Malnourished children with complications requiring acute phase treatment in a hospital, children with tuberculosis (diagnosis
based on WHO 2014 guidelines which have been incorporated in the national TB control guidelines of Bangladesh). The guidelines depend upon the
following five diagnostic principles (three out of five should be positive):
• Specific symptoms of TB
• Specific signs of TB
• Chest X-ray
• Mantoux test
• History of contact
Any congenital/acquired disorder affecting growth, i.e., known case of trisomy-21 or cerebral palsy; children on an exclusion diet for the treatment of
persistent diarrhea; having known history of soy, peanut or milk protein allergy
Severe anemia (< 8 mg/dl)
Antibiotic use (within last 15 days before the onset of intervention)
Ongoing maternal antibiotic usage for breastfeeding infants
Receiving concurrent treatment for another condition

a witness who is not associated with the study. The child’s
parent(s) will be provided with a copy of the signed consent form.
At the beginning of the study, information will be collected on the demographic characteristics of the participants (family income, standard/type of housing,
family structure, parental education, etc.). FRAs will collect anthropometry data by recording the child’s weight
using a digital scale with 2g precision (Seca, model 728,
Germany), length (Seca model 416 infantometer), and
mid-upper arm circumference (MUAC) to the nearest
millimeter (using a non-stretch tape). Z scores will be
calculated using the new child growth standards of the
World Health Organization [12]. Collection of anthropometric data will occur at weekly intervals throughout the
study.
Intervention arms

The trial will have 5-arms designed to compare the efficacy of alternative MDCF formulations in repairing
the gut microbiota of children with MAM compared
to the repair produced by the current kitchen prepared
MDCF-2 formulation. All the formulations are fortified
with equal amount of vitamins and minerals. Children
will be randomly assigned to one of the interventions
after enrolment.
Arm 1 - Reference control: kitchen-prepared MDCF2
Arm 2 - Individually packaged, pre-measured
sachets of MDCF-2 ingredients, combined and

reconstituted in the home setting prior to consumption
Arm 3 - MDCF-2 shelf-stable foil pouch formulation with green banana powder
Arm 4 - MDCF shelf-stable foil pouch formulation
with sweet potato instead of green banana
Arm 5 - Ready-to-use supplementary food (RUSF)
Table 2 provides an overview of the interventions.
Development, delivering & monitoring the interventions

Formulations in arm 1 and arm 2 will be prepared in a
kitchen setting. For the rest of the arms, test products
will be manufactured in an industrial setting. Each child
will receive 250 kcal per day of their assigned formulation. Due to differences in caloric density of the prototypes, the weight per serving of each formulation will be
adjusted to ensure equivalent energy provision (Table 2).
We have partnered with a large food manufacturer in
Bangladesh to develop the shelf-stable, packaged formulations. For this study, we will deliver the industry-made
formulations packaged in a trilaminar foil pouch after
sterilization. The kitchen-prepared formulations will not
be sterilized as these recipes will be delivered immediately after their preparation. A dedicated, BRC- and
HACCP-compliant Food Processing Laboratory has been
established at the factory site to prepare, package, and
sterilize the MDCF and RUSF.
A standardized production procedure is followed
throughout the project period to control the quality
of the formulations. Raw materials are at first passed
through a vigorous quality checking process. The materials are then roasted in a temperature controlled hot air

Active Comparator: Central kitchen-prepared MDCF-2. Children randomized to this arm will
receive 25g of kitchen-prepared version of MDCF-2 twice daily.

Experimental: ‘Jump-start’ version of MDCF-2. Freshly reconstituted MDCF-2 ingredients. Children randomized to this arm will receive individually packaged MDCF-2 ingredients, combined
into 21.7 g servings provided twice daily.

Experimental: MDCF-2 shelf-stable foil pouch prototype with green banana powder. Children
randomized to this arm will receive 25g of the shelf-stable foil pouch prototype with green
banana powder twice daily.

Experimental: MDCF-2 shelf-stable foil pouch prototype with sweet potato. Children randomized to this arm will receive 23.3g of this MDCF prototype with sweet potato twice daily.

Experimental: Ready-to-use supplementary food (RUSF). Children randomized to this arm will
receive 25g RUSF twice daily.

1

2

3

4

5

Arms

Table 2 Arms and Interventions

Dietary Supplement: Ready-to-use supplementary food (RUSF) arm. Locally-produced ready-touse supplementary food (RUSF) is used as part of a nutritional program to treat moderate acute
malnutrition in children over 6 months-of-age. RUSF is eaten directly from the package with no
dilution, mixing or cooking. RUSF contains rice, lentil, powdered low-fat milk, soybean oil, sugar,
and micronutrient mix.

Dietary Supplement: MDCF-2 shelf-stable foil pouch prototype with sweet potato. This shelfstable MDCF prototype contains chickpea flour, peanut flour, soybean flour, sweet potato, sugar,
soybean oil and micronutrient mix. This version of MDCF-2 will be prepared by an industry
partner following the formulation developed at icddr,b.

Dietary Supplement: MDCF-2 shelf-stable foil pouch prototype with green banana powder.
This shelf-stable foil pouch prototype of MDCF-2 contains chickpea flour, peanut flour, soybean
flour, green banana powder, sugar, soybean oil and micronutrient mix, prepared by an industry
partner following the formulation developed at icddr,b.

Dietary Supplement: Jump-start version of MDCF-2. Freshly reconstituted MDCF-2 ingredients.
This version of MDCF-2 is comprised of its individually packaged ingredients. Separate premeasured sachets of chickpea flour, peanut paste, soybean flour, green banana powder, sugar,
soybean oil and micronutrient mix will be combined and reconstituted prior to each feeding
session.

Dietary Supplement: Central kitchen-prepared version of MDCF-2. Kitchen-prepared MDCF-2
containing chickpea flour, peanut flour, soybean flour, green banana pulp, sugar, soybean oil and
micronutrient mix. This version of MDCF-2 will be freshly prepared in a central kitchen on a daily
basis and provided to participants on the same day.

Intervention
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oven followed by a grinding process using a heavy-duty
electric grinder to make fine powder/paste as appropriate. To prepare homogenous mixtures, the milled raw
materials are shifted to semi-automatic electric mixers to
prepare a smooth textured MDCF or RUSF paste. Each
step of food preparation, including cleaning, roasting,
particle size reduction, and blending, are closely monitored by the study personnel. The paste is then moved to
a semi-automatic filler machine in order to fill the trilaminar foil pouch without any direct physical touching by
factory personnel. An “Impulse Sealer Machine” is used
to achieve airtight sealing of the pouches. Sterilization is
performed in a retort machine at 121 °C and 0.208 MPa
pressure for a period of 20 minutes. This process ensures
a longer contamination-free shelf life while preserving
the organoleptic properties of the food. Before distribution to the study site, random samples from each batch
will be tested for organoleptic properties and for microbial contamination see Table 3.
Acceptability will be assessed at the feeding center
by using the 7-point Hedonic scale. A score of 7, corresponds to ‘like extremely’ while a score of 1 corresponds
to ‘dislike extremely’ [13].
Monitoring food consumption and collection of meta‑data

Each child will be offered approximately 25 grams of the
diet in each feeding session (Table 2). Feeding will take
place under the direct supervision of trained study personnel. The intervention diets are pre-weighed. Mothers will be instructed to collect all unconsumed food for
weigh-back so that the amount consumed by each child
can be calculated. Only water from the mug is allowed to
drunk; the amount of water consumed is also measured.

The quantity of MDCF or RUSF consumed will be monitored and calculated in every feeding session. Multiple
food frequency data and 24 hours dietary recall data will
also be collected.
Outcome measures

Primary Outcome Measure: Equivalence in the response
to MDCF-2 and a test MDCF formulation, based on the
change in representation of MDCF-2 responsive gut
bacterial taxa after 4-weeks of treatment. V4-16S rDNA
amplicons and shotgun sequencing datasets will be generated from faecal samples collected from each child
in each group prior to, during, and after treatment to
determine the abundances of MDCF-2 responsive bacterial taxa. Equivalence will be defined as the absence
of a statistically significant difference after 4-weeks of
treatment in the representation of faecal bacterial taxa
associated with the response to MDCF-2 in participants
receiving a test MDCF, compared to the representation
of these bacterial taxa in participants after receiving the
reference MDCF-2 formulation for 4-weeks. Other prespecified outcomes changes in the concentrations of
faecal protein biomarkers of gut inflammation [myeloperoxidase (Alpco, Salem, New Hampshire), neopterin
(GenWay Biotech, San Diego, California), calprotectin (BÜHLMANN fCAL, Schönenbuch, Switzerland),
lipocalin-2 (R&D Systems, USA), dual oxidase 2 (MyBioSource, USA)] and protein losing enteropathy [alpha1-antitrypsin (Biovendo Chandler, North Carolina)].
These proteins will be measured using commercially
available ELISA according to the kit manuals. Changes
in oxidation-reduction potential and pH of fecal samples will be quantified using a redox meter (PCE-228-R,

Table 3 Microbiological and Biochemical test
Parameters for Microbiological tests
Test name

Method

Acceptable limit
CFU/gm

Total plate count/Aerobic bacteria/APC

USFDA/BAM

<10,000

Total coliform/E. coli

USFDA/BAM

<10

Yeast and Mold Count

USFDA/BAM

<10

Salmonella

USFDA/BAM

Nil

Shigella

USFDA/BAM/ ISO

Nil

Bacillus cereus

USFDA/BAM/ ISO

<10

Staphylococci

USFDA/BAM/ ISO

<10

Enterobacteriaceae

USFDA/BAM/ ISO

<10

Parameters for Biochemical tests
Test name

Acceptable limit

pH

6.5-7.5

Moisture

<2.5% for dry food product
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PCE Instruments, Southampton, United Kingdom) and
pH meter (Hanna Instrument, USA), respectively. In
addition, changes in the abundances of 7000 circulating
plasma proteins that include biomarkers and mediators
of various facets of host physiology will be quantified
using the SomaScan-aptamer-based proteomics platform
(SomaLogic, Boulder CO, USA).
Sample size

The sample size was informed by the faecal 16S rRNA
gene amplicon datasets generated for the proof-of-concept study of 12 to 18-month-old Bangladeshi children
with MAM.11 In that study, we identified 209 bacterial
Amplicon Sequence Variants (ASVs) that were present
above 5 counts in at least 5% of the 939 faecal samples
analyzed from 118 participants. We calculated 95% confidence intervals (CI; mean ± 1.96 standard error) for
the change (delta) in abundance of each of the 209 ASVs
between day 0 (pre-intervention) and 4 weeks of intervention for the 59 children in the MDCF-2 treatment
group of the POC study. Using a bootstrapping approach
with ASV data from 5000 subsets of 20 children from the
MDCF-2 group and 5000 subsets of 20 children from
the RUSF group, we identified 121 ASVs whose mean
changes in abundance for the MDCF-2 subsets fell within
the 95% CI of the mean changes for the 59 MDCF-2 participants, but not in children who had received RUSF,
with 80% power (“MDCF-2-responsive ASVs”). Therefore, each arm will include a minimum of 20 children
who complete the study. Considering potential drop-outs
(15%), 23 children will be recruited per arm.
Collection, preparation and archiving of biological samples

All biological samples (blood and faeces) will be collected according to the standard operating procedures
(SOPs) described in our previous publications [11]. Five
millimeters of blood will be collected from each participant before and after the treatment phase (Fig. 1). Whole
blood samples will be centrifuged at 3000 x g for 10 minutes to separate the plasma [14]. Aliquots of plasma sample will be stored at -80 °C until analysis.
Faecal samples will be collected weekly during the runin, treatment and wash-out phases of the study. At the
site of collection, samples will be aliquoted into sterile,
pre-labelled 2 mL cryovials and immediately placed into
pre-charged liquid nitrogen dry cryo-shippers (within
20 minutes of their production by trial participants)
for transport back to the laboratory. At the laboratory,
vials will be placed on dry ice while they are organized and subsequently transferred to 9x9 freezer boxes.
These boxes will be maintained in a -80oC freezer prior
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to analysis. No additives, preservatives or media will be
added to the faecal samples.
Analysis plan

To assess the comparability of microbiota repair elicited by shelf-stable test formulations of MDCF-2 and
the reference kitchen prepared formulation, we will
sequence PCR amplicons generated from variable
region 4 of bacterial 16S rRNA genes present in DNA
isolated from faecal samples collected from participants in the different study arms immediately prior to
intervention (day 0) and at the end of intervention (day
28). ASV data will be processed using DADA2 [15] and
filtered as described [10]. We will calculate 95% confidence intervals of the mean change in abundance of
each of the MDCF-2-responsive ASVs identified in
this study, between day 0 and day 28, in children who
received the reference MDCF-2 formulation, as well as
the mean change in abundance for each of these ASVs
in participants receiving the test formulations. A test
formulation will be considered equivalent to the reference MDCF-2 if >70% of the MDCF-2-responsive ASVs
have mean changes in abundance in children consuming a test formulation between day 0 and day 28 that
fall within the 95% CI of their mean changes in abundance in the reference MDCF-2 arm. Another embodiment of the analysis of microbial community repair
elicited by the reference MDCF-2 and test formulations
will involve a comparison of their effects after 28 days
of treatment on the abundances of metagenome-assembled genomes (MAGs) identified by shotgun sequencing of the same faecal DNA samples used to produce
16S rDNA amplicons.
Exploratory outcomes will include the effects of the
test formulations on features of the plasma and faecal proteomes, including MDCF-2-responsive proteins that are associated with various facets of healthy
growth using approaches described in the MDCF-2
POC study [10].
Current status of enrolment

Enrolment for the study began on 31 October 2021. We
are currently recruiting study participants. The enrolment is expected to be completed by 31 December 2022.
Data confidentiality and archiving

Privacy, anonymity and confidentiality of data will be
strictly maintained. All trial related information will be
kept confidential and stored securely at the central office
in icddr,b. Codes will be used to depersonalise the data.
The linking code, electronic data files and paper forms
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are stored in a separate location under password protections or lock and key. Access to the data will be restricted
to the investigators.

Availability of data and materials
All data related to this study protocol are within the manuscript and its
supporting information files. Additional information is available from the corresponding author on reasonable request.

Discussion
The current version of MDCF-2 is freshly prepared in
local kitchens on a daily basis and distributed locally
on the same day without sterilization. Given the need
to identify a bioequivalent formulation that can be
produced at scale and distributed to other geographic
locales, we have designed this study of children with
MAM to test alternative shelf-stable prototypes of
MDCF-2 that each provide ~250 kcal/day, plus 70%
RDA of key micronutrients. Outcomes will include the
organoleptic acceptability of the prototypes and their
effects on microbiota repair over 4-weeks of intervention. Our goal is to identify a packaged, shelf-stable
formulation for advancing into larger, longer proof-ofconcept studies that evaluate efficacy using clinicallyrelevant growth outcomes. One weakness of this study
is that it is not possible to attain full blinding since the
test prototypes are not packaged in a similar manner.
In conclusion, this study aims to establish the acceptability of a scalable, shelf-stable formulation that is
bioequivalent to MDCF-2 with respect to microbiota
repair in 8-12-month-old Bangladeshi children with
moderate acute malnutrition. The results of this study
will inform the selection of a shelf-stable formulation of
its efficacy for treating of moderate acute malnutrition.
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